September 19, 2019

Pseudobulbar Treatment Market to Register Substantial Expansion by 2027

Pseudobulbar Treatment Market Introduction

Pseudobulbar affect (PBA) is a disinhibition syndrome characterized by uncontrolled crying or laughter. It could occur in association with various neurological diseases such as amyotrophic lateral sclerosis, extrapyramidal & cerebellar disorders, multiple sclerosis, traumatic brain injury, Alzheimer’s disease, stroke, and brain tumor. In pseudobulbar affect (PBA), serotonin and glutamate pathways are disrupted. According to the Jobson Medical Information LLC, more than 1.5 million people in the U.S. are affected by pseudobulbar affect (PBA).

Global Pseudobulbar Treatment Market – Competitive Landscape

The global pseudobulbar treatment market is highly fragmented, with several domestic players holding major share in respective regions. Low cost of manufacturing, easy availability of generic products, and large volume business for antidepressant drugs have attracted a number of domestic manufacturers in the market. Major players operating in the global pseudobulbar treatment market focus on business expansion and mergers & collaborations.

To Know the Segments Analyzed in the Pseudobulbar Treatment Market Report, Ask for a Brochure Pseudobulbar Treatment Market

Merck & Co., Inc.

Merck & Co., Inc. is a global health care company that develops, manufactures, markets, and sells generic antidepressants drugs. The company’s products are utilized by health care professionals in more than 100 countries. It periodically invests in acquisitions that provide opportunities to supplement organic growth as well as strengthen its product portfolio and establish presence in emerging markets.

Merck & Co., Inc. has wide presence in various regions including Asia Pacific, Europe, Middle East & Africa, and Latin America. It offers innovative health solutions in more than 140 countries.

Pfizer, Inc.

Pfizer, Inc. is a multinational company with strong presence in the antidepressant drugs market in North America. It is a global pharmaceutical company that develops, manufactures, and markets prescription medicines in 11 therapeutic segments, including cardiovascular, oncology, neuroscience, pain, and infectious diseases. It operates through two business units: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

GlaxoSmithKline plc

GlaxoSmithKline is a global pharmaceutical company engaged in research, development, and manufacture of innovative pharmaceutical medicines, vaccines, and consumer health care products. In 2018, GlaxoSmithKline invested around US$ 4.60 Mn in research and development of pipeline products.

Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. is a key producer of generic medicines and a recognized leader in innovative and specialty pharmaceuticals across the globe. The company delivers high-quality and patient-centric health care solutions.

It has a broad generic product portfolio, with more than 35,000 products in nearly every therapeutic area. The company primarily operates through two business segments: generic medicines and specialty medicines. Teva Pharmaceutical Industries Ltd. markets its pseudobulbar treatment drug under its generic medicines business segment.

Eli Lilly and Company

Eli Lilly and Company is a health care company that combines discovery with caring to make lives of people across the world better. The company operates through two major business segments: animal health and human pharmaceutical products.

It markets some of its human pharmaceutical products in cooperation with other pharmaceutical companies including Boehringer Ingelheim GmbH, Shionogi, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Daiichi Sankyo Company, Limited.

Other players operating in the global pseudobulbar treatment market include Allergan plc and Avanir Pharmaceuticals Inc.

To Know More about TMRs Unique Offerings for Pseudobulbar Treatment Market, Request a Custom Report Pseudobulbar Treatment Market

Global Pseudobulbar Treatment Market – Dynamics

Anticipated Launch & Commercialization of Drugs for Pseudobulbar Treatment to Drive Market

A large number of drug candidates are in different stages of clinical trial approval in the U.S. and Europe. The anticipated launch and commercialization of these products is expected to propel the global pseudobulbar treatment market during the forecast period.

Increase in R&D Expenditure to Propel Market

Emergence of novel techniques for the development of drugs with fewer side effects drive the global pseudobulbar treatment market. Increase in awareness about the disease state & required clinical needs and rise in number of people suffering from pseudobulbar affect are encouraging manufacturers operating in the pseudobulbar treatment market to invest in the development of novel drugs effective in the treatment of the condition.

Global Pseudobulbar Treatment Market – Segmentation

In terms of drug type, the global market can be classified into:

  • Selective Serotonin Reuptake Inhibitors
  • Tricyclic Antidepressants
  • Dextromethorphan Hydrobromide and Quinidine Sulfate (Nuedexta)
  • Others